pharmaphorum September 6, 2024
Our round-up of financings in the biotech sector this week is led by BioAge Lab’s filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private rounds for eGenesis, Navigator, and Circle Pharma.
The decision by BioAge to try for a Nasdaq listing comes after it raised $170 million in a fourth-round financing earlier this year, tapping into the investment frenzy for companies with assets in the clinic for obesity.
The company is focusing on the development of oral apelin receptor (APJ) agonist azelaprag, currently in a phase 2 trial in combination with Eli Lilly’s FDA-approved obesity therapy Zepbound (tirzepatide), with results due in the third quarter of 2025.
The biotech believes that azelaprag...
Today's Sponsors
Today's Sponsor